{"analyses":[{"ciLowerLimit":"0.31","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.57","groupDescription":"AFP \\<400 ng/mL and stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.42","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.35","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.73","groupDescription":"AFP \\>/=400 ng/mL and stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.51","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.79","upperLimit":"5.62","value":"3.98"},{"groupId":"OG001","lowerLimit":"7.06","upperLimit":"9.66","value":"8.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"title":"AFP <400 ng/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.58","upperLimit":"3.98","value":"2.79"},{"groupId":"OG001","lowerLimit":"4.17","upperLimit":"6.90","value":"5.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"AFP >/=400 ng/mL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \\>/= 5 millimeters (mm). Subpopulations with baseline AFP \\<400 ng/mL and AFP\\>/= 400 ng/mL were analyzed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEDIAN","populationDescription":"Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"PFS-INV Per RECIST v1.1 by Baseline AFP in the Global Population","type":"SECONDARY","unitOfMeasure":"months"}